Maternal misuse of prescription opioids and illicit drugs such as, heroin and non-pharmaceutical fentanyl analogs has increased in the last 2 decades and one in 5 women reported misuse of opioids. Medications for opioid use disorder (MOUD) are recommended for treating pregnant women with opioid use disorder (OUD). MOUD is effective in reducing cravings and negative outcomes, yet treatment is underutilized and varies in integration and intensity of resources across health systems. Exploring perceptions of MOUD delivery among pregnant/parenting women promises to uncover and address the underlying challenges to treatment, a perspective that may be different for providers and stakeholders. Therefore, our main purpose is to elicit patients’ experiences and perceptions of MOUD, associated access to treatment, and availability of supportive resources during pregnancy/postpartum to inform OUD treatment.
Methods:
Through a qualitative research approach we gathered data from individual interviews/focus group discussions for this pilot study. Pregnant and postpartum parenting women (n = 17) responded to questions related to perceptions of MOUD, access to treatment, and availability of social and psychosocial resources. Data were collected, transcribed, and coded (by consensus) and emerging themes were analyzed using grounded theory methodology.
Results:
Emerging themes revealed positive uptake and perceptions of MOUD, continuing gaps in knowledge, negative impact of stigmatization, and limited access to programs and resources. Supportive relationships from family, peers, healthcare providers and child welfare staff, and co-located services were perceived as positive motivators to recovery.
Conclusions:
Through the unique lenses of women with lived experience, this study revealed several themes that can be transformative for women. Overall perceptions of MOUD were positive and likely to facilitate uptake and promote positive recovery outcomes. Bridging knowledge gaps will reduce anxieties, fears about neonatal opioid withdrawal syndrome and adverse maternal outcomes. Additionally, a deeper understanding of stigmatization and relationships can inform an integrated patient-centered approach to OUD treatment.
Hirai AH, Ko JY, Owens PL, Stocks C, Patrick SW. Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses in the US, 2010-2017 [published correction appears in JAMA. 2021 Jun 8;325(22):2316]. JAMA. 2021;325(2):146-155. doi:10.1001/jama.2020.24991
Collier AY, Molina RL. Maternal mortality in the United States: Updates on trends, causes, and solutions. Neoreviews. 2019;20(10):e561–e574. doi:10.1542/neo20-10-e561
4.
MartinCELonginakerNTerplanM.Recent trends in treatment admissions for prescription opioid abuse during pregnancy. J Subst Abuse Treat. 2015;48(1):37-42. doi:10.1016/j.jsat.2014.07.007
5.
JosephKSBoutinALisonkovaS, et al. Maternal mortality in the United States. Obstet Gynecol. 2021;137(5):763-771. doi:10.1097/AOG.0000000000004361
6.
HaightSC.Opioid use disorder documented at delivery hospitalization—United States, 1999–2014. MMWR Morb Mortal Wkly Rep. 2018;67:845-849. doi:10.15585/mmwr.mm6731a1
7.
KoJY.Vital signs: prescription opioid pain reliever use during pregnancy—34 U.S. jurisdictions, 2019. MMWR Morb Mortal Wkly Rep. 2020;69:898-903. doi:10.15585/mmwr.mm6928a1
8.
GreenCA.Gender and use of substance abuse treatment services. Alcohol Res Health J Natl Inst Alcohol Abuse Alcohol. 2006;29(1):55-62.
Substance Abuse and Mental Health Services Administration. Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants. Rockville, MD: SAMHA; 2018.
ToliaVNPatrickSWBennettMM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med. 2015;372(22):2118-2126. doi:10.1056/NEJMsa1500439
14.
PatrickSWDavisMMLehmanCUCooperWO.Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol Off J Calif Perinat Assoc. 2015;35(8):667. doi:10.1038/jp.2015.63
15.
PatrickSWSchumacherREBenneyworthBDKransEEMcAllisterJMDavisMM.Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012;307(18):1934-1940. doi:10.1001/jama.2012.3951
16.
BehnkeMSmithVC, Committee on Substance Abuse, Committee on Fetus and Newborn. Prenatal substance abuse: short-and long-term effects on the exposed fetus. Pediatrics. 2013;131(3):e1009-e1024. doi:10.1542/peds.2012-3931
17.
U. S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Center for Substance Abuse Treatment, 2018. Treatment Improvement Protocol (TIP) 63: Medications for Opioid Use Disorder. HHS Publication No. PEP21-02-01-002. First released 2018. Revised 2019, 2020 and Rockville, MD: Substance Abuse and Mental Health Services Administration.
18.
ReddyUMDavisJMRenZGreeneMF, Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes Workshop Invited Speakers. Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes: executive summary of a joint workshop by the eunice kennedy shriver national institute of child health and human development, American college of obstetricians and gynecologists, American academy of pediatrics, society for maternal-fetal medicine, centers for disease control and prevention, and the march of dimes foundation. Obstet Gynecol. 2017;130(1):10-28. doi:10.1097/AOG.0000000000002054
19.
JonesHEFischerGHeilSH, et al. Maternal opioid treatment: human experimental research (MOTHER) – approach, issues, and lessons learned. Addict Abingdon Engl. 2012;107(1):28-35. doi:10.1111/j.1360-0443.2012.04036.x
20.
JonesHEFinneganLPKaltenbachK.Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs. 2012;72(6):747-757. doi:10.2165/11632820-000000000-00000
ChouRKorthuisPTWeimerM, et al. Medication-Assisted Treatment Models of Care for Opioid Use Disorder in Primary Care Settings. Agency for Healthcare Research and Quality (US); 2016.
23.
MitchellPSamselSCurtinKM, et al. Geographic disparities in access to medication for opioid use disorder across US census tracts based on treatment utilization behavior. Soc Sci Med. 2022;302:114992. doi:10.1016/j.socscimed.2022.114992
24.
AndrillaCHAPattersonDG.Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder. J Rural Health. 2022;38(1):87-92. doi:10.1111/jrh.12569
25.
CantorJPowellDKofnerASteinBD.Population-based estimates of geographic accessibility of medication for opioid use disorder by substance use disorder treatment facilities from 2014 to 2020. Drug Alcohol Depend. 2021;229:109107. doi:10.1016/j.drugalcdep.2021.109107
26.
U. S. Department of Health and Human Services Administration. Substance Abuse and Mental Health Services Administration, 2016. A collaborative approach to the treatment of pregnant women with opioid use disorders. HHS Publication No. (SMA)16-4978. Rockville, MD. Substance Abuse and Mental Health Services Administration. Accessed May 30, 2023. https:// store.samhsa.gov/sites/default/files/sma16-4978.pdf
27.
BoeriMLamonicaAKTurnerJMParkerAMurphyGBocconeC.Barriers and motivators to opioid treatment among suburban women who are pregnant and mothers in caregiver roles. Front Psychol. 2021;12:688429. https://www.frontiersin.org/articles/10.3389/fpsyg.2021.688429
28.
Titus-GloverDShayaFTWelshC, et al. Opioid use disorder in pregnancy: leveraging provider perceptions to inform comprehensive treatment. BMC Health Serv Res. 2021;21:215. doi:10.1186/s12913-021-06182-0
29.
JonesCDueaSGriggsKJohnstoneWKinseyD.Improving outcomes of mothers with opioid use disorder using a community collaborative model. J Prim Care Community Health. 2021;12:21501327211052401. doi:10.1177/21501327211052401
30.
GhideiLRamosSZBrousseauECClarkeJG.Prison: pipeline to women’s preventative health. R I Med J 2013. 2018;101(8):23-26.
31.
FrazerZMcConnellKJanssonLM.Treatment for substance use disorders in pregnant women: motivators and barriers. Drug Alcohol Depend. 2019;205:107652. doi:10.1016/j.drugalcdep.2019.107652
32.
KingZKramerCLatkinCSufrinC.Access to treatment for pregnant incarcerated people with opioid use disorder: perspectives from community opioid treatment providers. J Subst Abuse Treat. 2021;126:108338. doi:10.1016/j.jsat.2021.108338
33.
StoneR.Pregnant women and substance use: fear, stigma, and barriers to care. Health Justice. 2015;3(1):2. doi:10.1186/s40352-015-0015-5
34.
WolfsonLSchmidtRAStinsonJPooleN.Examining barriers to harm reduction and child welfare services for pregnant women and mothers who use substances using a stigma action framework. Health Soc Care Community. 2021;29(3):589-601. doi:10.1111/hsc.13335
35.
FallettaLHamiltonKFischbeinRAultmanJKinneyBKenneD.Perceptions of child protective services among pregnant or recently pregnant, opioid-using women in substance abuse treatment. Child Abuse Negl. 2018;79:125-135. doi:10.1016/j.chiabu.2018.01.026
GillPStewartKTreasureEChadwickB.Methods of data collection in qualitative research: interviews and focus groups. Br Dent J. 2008;204(6):291-295. doi:10.1038/bdj.2008.192
38.
TongASainsburyPCraigJ.Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349-357. doi:10.1093/intqhc/mzm042
39.
GuestGBunceAJohnsonL.How many interviews are enough?: An experiment with data saturation and variability. Field Methods. 2006;18(1):59-82. doi:10.1177/1525822X05279903
40.
SinghSEstefanA.Selecting a grounded theory approach for nursing research. Glob Qual Nurs Res. 2018;5:2333393618799571. doi:10.1177/2333393618799571
41.
AduP.A Step-by-Step Guide to Qualitative Data Coding. Routledge; 2019. doi:10.4324/9781351044516
KransEEPatrickSW.Opioid use disorder in pregnancy: Health policy and practice in the midst of an epidemic. Obstet Gynecol. 2016;128(1):4-10. doi:10.1097/AOG.0000000000001446
44.
BrownBSBassUFGauveySKKozelNJ.Staff and client attitudes toward methadone maintenance. Int J Addict. 1972;7(2):247-255. doi:10.3109/10826087209026777
45.
ClearyBJDonnellyJMStrawbridgeJD, et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol. 2011;204(2):139.e1-139.e9. doi:10.1016/j.ajog.2010.10.004
46.
StancliffSElana MyersJSteinerSDruckerE.Beliefs about methadone in an inner-city methadone clinic. J Urban Health. 2002;79(4):571-578. doi:10.1093/jurban/79.4.571
47.
WooJBhaleraoABaworM, et al. “Don’t judge a book by its cover”: a qualitative study of methadone patients’ experiences of stigma. Subst Abuse Res Treat. 2017;11:1178221816685087. doi:10.1177/1178221816685087
48.
CioeKBiondiBEEaslyRSimardAZhengXSpringerSA.A systematic review of patients’ and providers’ perspectives of medications for treatment of opioid use disorder. J Subst Abuse Treat. 2020;119:108146. doi:10.1016/j.jsat.2020.108146
49.
Fiddian-GreenAGubriumAHarringtonCEvansEA.Women-reported barriers and facilitators of continued engagement with medications for opioid use disorder. Int J Environ Res Public Health. 2022;19(15):9346. doi:10.3390/ijerph19159346
50.
RichardELSchalkoffCAPiscalkoHM, et al. “You are not clean until you’re not on anything”: perceptions of medication-assisted treatment in rural Appalachia. Int J Drug Policy. 2020;85:102704. doi:10.1016/j.drugpo.2020.102704
51.
GoodmanDJSaundersECWolffKB.In their own words: a qualitative study of factors promoting resilience and recovery among postpartum women with opioid use disorders. BMC Pregnancy Childbirth. 2020;20(1):178. doi:10.1186/s12884-020-02872-5
52.
HunterSBDoppAROberAJUscher-PinesL.Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: a qualitative study. J Subst Abuse Treat. 2021;124:108288. doi:10.1016/j.jsat.2021.108288
53.
SuenLWCastellanosSJoshiNSatterwhiteSKnightKR.“The idea is to help people achieve greater success and liberty”: a qualitative study of expanded methadone take-home access in opioid use disorder treatment. Subst Abuse. 2022;43(1):1143-1150. doi:10.1080/29767342.2022.2060438
54.
KampmanKJarvisM.American society of addiction medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358-367. doi:10.1097/ADM.0000000000000166
55.
MooreKESiebertSLKromashROwensMDAllenDC.Negative attitudes about medications for opioid use disorder among criminal legal staff. Drug Alcohol Depend Rep. 2022;3:100056. doi:10.1016/j.dadr.2022.100056
56.
DuberHCBarataIACioè-PeñaE, et al. Identification, management, and transition of care for patients with opioid use disorder in the emergency department. Ann Emerg Med. 2018;72(4):420-431. doi:10.1016/j.annemergmed.2018.04.007
57.
SporerKA.Buprenorphine: a primer for emergency physicians. Ann Emerg Med. 2004;43(5):580-584. doi:10.1016/j.annemergmed.2003.11.006
58.
GuoCZD’OnofrioGFiellinDA, et al. Emergency department-initiated buprenorphine protocols: a national evaluation. J Am Coll Emerg Physicians Open. 2021;2(6):e12606. doi:10.1002/emp2.12606
59.
HeilSHJonesHEArriaA, et al. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat. 2011;40(2):199-202. doi:10.1016/j.jsat.2010.08.011
60.
TimkoCSchultzNRCucciareMAVittorioLGarrison-DiehnC.Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22-35. doi:10.1080/10550887.2016.1100960
61.
MaddenEF.Intervention stigma: how medication-assisted treatment marginalizes patients and providers. Soc Sci Med. 2019;232:324-331. doi:10.1016/j.socscimed.2019.05.027
62.
OlsenYSharfsteinJM.Confronting the stigma of opioid use disorder—and its treatment. JAMA. 2014;311(14):1393-1394. doi:10.1001/jama.2014.2147
63.
ShidlansikLAdelsonMPelesE.Knowledge and stigma regarding methadone maintenance treatment among personnel of methadone maintenance treatment and non-methadone maintenance treatment addiction facilities in Israel. J Addict Dis. 2017;36(1):30-37. doi:10.1080/10550887.2016.1235404
64.
Andraka-ChristouBGabrielMMadeiraJSilvermanRD.Court personnel attitudes towards medication-assisted treatment: a state-wide survey. J Subst Abuse Treat. 2019;104:72-82. doi:10.1016/j.jsat.2019.06.011
65.
HowardHFreemanKClarkK. U.S.Survey of shared decision making use for treating pregnant women presenting with opioid use disorder. Subst Use Misuse. 2019;54(13):2241-2250. doi:10.1080/10826084.2019.1644524
66.
StoltmanJJKLanderLRPatrickJHTerplanMJonesHE. Interest in co-located reproductive and sexual health services among women and men receiving medication for opioid use disorder in an outpatient treatment clinic. Front Psychiatry. 2022;13:910389. Accessed May 29, 2023. https://www.frontiersin.org/articles/10.3389/fpsyt.2022.910389
67.
CollierKWMacAfeeLKKennyBMMeyerMC.Does co-location of medication assisted treatment and prenatal care for women with opioid use disorder increase pregnancy planning, length of interpregnancy interval, and postpartum contraceptive uptake?J Subst Abuse Treat. 2019;98:73-77. doi:10.1016/j.jsat.2018.12.001
68.
SaundersECMooreSKWalshO, et al. “It’s way more than just writing a prescription”: a qualitative study of preferences for integrated versus non-integrated treatment models among individuals with opioid use disorder. Addict Sci Clin Pract. 2021;16(1):8. doi:10.1186/s13722-021-00213-1
69.
Substance Abuse and Mental Health Services Administration (SAMHSA). Community Engagement: An Essential Component of an Effective and Equitable Substance Use Prevention System. SAMHSA; 2022. http://store.samhsa.gov
HarrisRACampbellKCalderbankT, et al. Integrating peer support services into primary care-based OUD treatment: lessons from the Penn integrated model. Healthc Amst Neth. 2022;10(3):100641. doi:10.1016/j.hjdsi.2022.100641
FreyJHFontanaA.The group interview in social research. Soc Sci J. 1991;28(2):175-187. doi:10.1016/0362-3319(91)90003-M
74.
RosendahlJGawlyttaRResselE, et al. Efficacy of group therapy to reduce mental distress in women with non-metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. Psychooncology. 2023;32(3):331-341. doi:10.1002/pon.6082
75.
HallMTWilfongJHuebnerRAPoszeLWillauerT.Medication-assisted treatment improves child permanency outcomes for opioid-using families in the child welfare system. J Subst Abuse Treat. 2016;71:63-67. doi:10.1016/j.jsat.2016.09.006
76.
FreisthlerBMaguire-JackKYoonSDellorEWolfJP.Enhancing permanency in children and families (EPIC): a child welfare intervention for parental substance abuse. BMC Public Health. 2021;21(1):780. doi:10.1186/s12889-021-10668-1
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
